Strides Arcolab promoter setting up fund to invest in high-growth firms

Arun Kumar is believed to be finalising a $1-bn deal to exit the specialties injectable business

Image
Raghuvir Badrinath Bangalore
Last Updated : Jan 29 2013 | 2:34 PM IST

Arun Kumar, the reclusive first-generation promoter of Bangalore-based pharma company Strides Arcolab Ltd, is understood to be actively involved in creating a family office type of fund to channel his personal wealth into fast-emerging companies. Kumar, who is believed to be finalising a $1-billion deal with global pharma majors to exit the specialties injectable business in Strides Arcolab, is scanning the landscape for a clutch of investments, say sources.

Kumar, along with his partner K R Ravishankar, has formed an investment vehicle for these investments and will bring in funds as and when an opportunity arises. Kumar had earlier confirmed to Business Standard he had made an investment in Mysore-based medical equipment company Skanray Healthcare. It is understood that he has made another investment and is looking to scale it up in the near future quite aggressively.

Vishwaprasad Alva, the owner of Skanray Healthcare, says Kumar is pretty high on compliance issues and takes quick decisions. “We had lot of options before us to raise funds. But we decided to go ahead with Arun Kumar as there was a quick connect and his understanding of the sector. He was also pretty quick in taking decision which helped us a lot.”

Kumar and Ravishankar will be joining the likes of Piramals, Azim Premji and N R Narayana Murthy to set up active family offices to invest and manage their wealth and also encourage entrepreneurs. Kumar, however, declined to share details with Business Standard, stating it was a private matter and he had no comments to add.

He founded Strides Arcolab in the 1990s and during the past five years, the company has grown aggressively by acquiring and divesting assets globally and is on the cusp of a mega deal, which will propel Strides Arcolab into a high growth orbit from its current annualised revenue rate of close to $600 million.

Kumar, a commerce graduate, began his career in the exports department of Bombay Drug House Ltd and was soon promoted to head the international division. He also served as general manager of British Pharmaceuticals Laboratories Ltd before starting Strides Arcolab.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 23 2013 | 12:22 AM IST

Next Story